Clinical trial · no report yet · Phase 2
TRADE DXd
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
- NCT06533826 ↗
- Recruiting
- Ana C Garrido-Castro, MD
- 53 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 24 | |
| Podcasts | 22 | |
| X threads | 7 |
The trial
ClinicalTrials.gov- Official title
- A Phase II Non-comparative Trial of Datopotamab Deruxtecan (Dato-DXd) or Trastuzumab Deruxtecan (T-DXd) in Patients With Metastatic HER2-negative (HER2-low or HER2-0) Breast Cancer After Progression on Prior Antibody Drug Conjugate Therapy
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Breast Cancer; HER2-low Breast Cancer; Metastatic Breast Cancer; HER2-negative Breast Cancer
- Interventions
- Trastuzumab Deruxtecan; Datopotamab Deruxtecan
- Arms
- Arm A (ADC1 T-DXd HR+) · Experimental
- Arn B (ADC1 T-DXd HR-) · Experimental
- Arm C (ADC1 Dato-DXd HR+) · Experimental
- Arm D (ADC1 Dato-DXd HR-) · Experimental
- Arm E (ADC2 Dato-DXd HR+) · Experimental
- Arm F (ADC2 Dato-DXd HR-) · Experimental
- Arm G (ADC2 T-DXd HR+) · Experimental
- Arm H (ADC2 T-DXd HR-) · Experimental
- Enrollment
- 357 (estimated)
- Primary outcomes
- Objective Response Rate in ADC1 (Group 1) Cohort
- Objective Response Rate in ADC2 (Group 2) Cohort
- Sponsor
- Ana C Garrido-Castro, MD with AstraZeneca, Translational Breast Cancer Research Consortium
- Start
- Oct 29, 2024
- Primary completion
- Jan 1, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06533826 · updated Aug 26, 2026